Renalytix (RENXF) Price & Analysis

Compare

7 Followers

RENXF Stock Chart & Stats

$0.08

Market closed

$0.08

Day’s Range― - ―

52-Week Range$0.04 - $0.18

Previous CloseN/A

VolumeN/A

Average Volume (3M)35.00

Market Cap

$19.46M

Enterprise Value$26.40M

Total Cash (Recent Filing)$9.63M

Total Debt (Recent Filing)$8.21M

Price to Earnings (P/E)―

Beta0.04

Next Earnings

Mar 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding437,018,680

10 Day Avg. Volume0

30 Day Avg. Volume35

Financial Highlights & Ratios

PEG Ratio0.01

Price to Book (P/B)-1.38

Price to Sales (P/S)3.23

P/FCF Ratio-0.54

Enterprise Value/Market Cap1.36

Enterprise Value/Revenue11.13

Enterprise Value/Gross Profit56.42

Enterprise Value/Ebitda-1.14

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth And Gross Margin ImprovementRevenue and gross-margin improvements signal improving unit economics: higher realized price or mix and lower per-test cost. If sustained, this trend supports scaled test profitability as volumes grow and fixed costs are absorbed, improving long-term cash conversion and strategic optionality.

Proprietary Diagnostic Platform And ML AlgorithmsA differentiated diagnostic combining biomarkers, clinical data and ML creates a durable competitive moat: clinical validation, algorithmic IP, and data accumulation raise barriers to entry, aid provider adoption and reimbursement discussions, and underpin long-term commercial scaling.

Operating Cash Burn Is Improving Versus Prior YearA material reduction in cash burn year-over-year reflects operational progress and cost control. Improved cash outflows reduce near-term financing pressure, extend runway, and increase the probability the company can execute commercialization and reimbursement initiatives without immediate dilutive raises.

Bears Say

Negative Shareholders' EquityNegative equity signals cumulative losses have eroded book capital, restricting financial flexibility. It raises counterparty and regulator concerns, limits borrowing capacity, and typically forces reliance on dilutive equity or distressed financing, increasing long-term funding risk.

Continued Heavy Cash Burn And FCF DeficitsSustained negative free cash flow requires external capital to fund operations and commercialization. Repeated financings can dilute shareholders, shift management focus to capital raises, and create execution risk if market access tightens, undermining long-term plan delivery.

Large Net Losses And Distant BreakevenExtremely negative net margins show the cost base far exceeds revenues, meaning profitability depends on substantial volume growth or cost reduction. This structural gap increases execution risk: if adoption or reimbursement stalls, losses and runway pressure could intensify.

Renalytix News

Renalytix CEO Boosts Stake as Kidney Disease Test Rollout Advances

Renalytix ( ($GB:RENX) ) has provided an announcement. Renalytix said Chief Executive James McCullough has increased his stake...

24d ago

Renalytix CFO Increases Stake as KidneyintelX.dkd Deployment Expands

Renalytix ( ($GB:RENX) ) just unveiled an update. Renalytix plc reported that interim Chief Financial Officer Joel Jung...

24d ago

Renalytix CFO Increases Stake as Kidney Disease Test Gains Traction

Renalytix ( ($GB:RENX) ) has provided an announcement. Renalytix announced that interim Chief Financial Officer Joel Jung purchased...

25d ago

Renalytix CEO Increases Stake Amid Expansion of Kidney Disease Test

Renalytix ( ($GB:RENX) ) just unveiled an update. Renalytix plc announced that Chief Executive Officer James McCullough purchased...

25d ago

Renalytix Eyes Revenue Growth as Kidney Diagnostic Expands U.S. Footprint

The latest announcement is out from Renalytix ( ($GB:RENX) ). Renalytix reported unaudited first-half fiscal 2026 revenues of...

26d ago

Renalytix Adds Three U.S. Kidney Care Integrations and Deepens Tempus AI Collaboration

Renalytix ( ($GB:RENX) ) has shared an announcement. Renalytix has expanded the clinical footprint of its kidneyintelX.dkd test...

2M ago

Renalytix Secures Shareholder Support at AGM and Advances Kidney Disease Diagnostics

Renalytix ( ($GB:RENX) ) has provided an announcement. Renalytix announced that all resolutions were passed at its Annual...

3M ago

Renalytix Expands Kidney Disease Test Adoption and Strategic Partnerships

Renalytix ( ($GB:RENX) ) has provided an update. Renalytix has provided an update on its strategic initiatives ahead...

3M ago

Renalytix AI Reports Strong Growth and Strategic Expansion

Renalytix AI Plc ( ($RENXF) ) has released its Q4 earnings. Here is a breakdown of the information...

3M ago

Renalytix’s KidneyIntelX.dkd Test Gains Recognition for Advancing CKD Management

Renalytix ( ($GB:RENX) ) has issued an update. Renalytix announced the publication of pivotal data on its kidneyintelX.dkd...

4M ago

RENXF FAQ

What was Renalytix’s price range in the past 12 months?

Renalytix lowest stock price was $0.04 and its highest was $0.18 in the past 12 months.

What is Renalytix’s market cap?

Renalytix’s market cap is $19.46M.

When is Renalytix’s upcoming earnings report date?

Renalytix’s upcoming earnings report date is Mar 26, 2026 which is in 17 days.

How were Renalytix’s earnings last quarter?

Currently, no data Available

Is Renalytix overvalued?

According to Wall Street analysts Renalytix’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Renalytix pay dividends?

Renalytix does not currently pay dividends.

What is Renalytix’s EPS estimate?

Renalytix’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Renalytix have?

Renalytix has 437,018,680 shares outstanding.

What happened to Renalytix’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Renalytix?

Currently, no hedge funds are holding shares in RENXF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Renalytix

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.